Pharmaceuticals - Multinational
Pfizer Ltd. is a leading pharmaceutical company in India. It is engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company was founded in 1950. Pfizer has grown to become a significant player in the Indian pharmaceutical industry. The headquarters of the company is located in Mumbai, Maharashtra. Pfizer's main products include Lipitor (atorvastatin), Prevenar 13 (pneumococcal conjugate vaccine), and Eliquis (apixaban). The company also offers medicines for various therapeutic areas. This includes cardiovascular, pain management, and women's health. Pfizer falls under the pharmaceutical and biotechnology sector. Read More...
No data available
No data available
Particulars (in ₹ Cr.) | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 237.76 | 16.63 | 123.19 | 102.74 | 87.21 |
Net Cash used in Investing Activities | -78.87 | 232.35 | 7.46 | -73.08 | -68.03 |
Net Cash used in Financing Activities | -95.20 | -75.89 | -33.82 | -46.02 | -14.71 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 2,373.68 | 2,525.81 | 2,673.64 | 2,319.67 | 2,335.67 |
Total Expenses | 1,635.56 | 1,734.80 | 1,900.75 | 1,650.95 | 1,693.18 |
Profit Before Tax | 746.07 | 824.01 | 772.89 | 668.72 | 642.49 |
Profit After Tax | 551.33 | 623.93 | 612.56 | 497.61 | 509.13 |
Operating Profit after Depreciation | 753.53 | 804.40 | 783.38 | 683.83 | 653.34 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 712.71 | 749.25 | 840.96 | 864.74 | 941.91 |
Total Non Current Assets | 1,490.97 | 1,507.39 | 1,504.03 | 1,341.19 | 1,357.15 |
Total Current Assets | 2,737.81 | 2,493.34 | 2,396.48 | 1,924.71 | 3,048.25 |
TOTAL ASSETS | 4,228.78 | 4,000.73 | 3,900.51 | 3,265.90 | 4,405.40 |
Total Shareholder's Fund | 3,595.54 | 3,207.30 | 2,864.41 | 2,393.04 | 3,395.49 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 256.84 | 355.68 | 667.08 | 427.33 | 323.18 |
Net Cash used in Investing Activities | 53.70 | -36.05 | -575.02 | -468.84 | 1,530.32 |
Net Cash used in Financing Activities | -235.14 | -345.79 | -180.51 | -1,571.07 | -163.52 |
No data available
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 588.59 | 562.86 | 546.63 | 539.97 | 575.21 |
Total Expenses | 399.34 | 385.37 | 357.20 | 387.42 | 392.60 |
Profit Before Tax | 215.23 | 202.62 | 243.86 | 175.94 | 200.52 |
Profit After Tax | 158.35 | 150.71 | 178.86 | 129.98 | 148.96 |
Operating Profit after Depreciation | 232.32 | 219.33 | 264.56 | 188.40 | 218.68 |
₹35/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Pfizer Ltd | ₹4,954.15 | ₹22,664.11 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
11 Nov 2024, 09:10 am
22 Oct 2024, 11:07 am
10 Aug 2024, 11:15 am
23 Jul 2024, 12:10 pm
18 May 2024, 09:40 am
View More